We're looking forward to joining our peers in November at #ACAAI26 to share the latest on our bispecific antibody candidate targeting atopic diseases. Learn more about the upcoming presentation and stay tuned for full results: bit.ly/4yg85DP

We're pleased to share that we will present new data at #ESMO26, highlighting our investigational antibody-drug conjugate therapy in combination with other cancer medicines for small cell lung cancer. Tune in next month for more: bit.ly/4xWBmn1

We're proud to announce positive results from a global Phase 3 trial conducted in partnership with @argenx, evaluating a potential treatment for autoimmune myositis. Read about the results: bit.ly/4x827Ff

Today we announced Q2 earnings results and updates on our pipeline, including recent designations from the EMA and U.S. FDA that demonstrate our progress toward making much-needed therapies for hard-to-treat diseases available to patients globally. bit.ly/4gfdAwL

#NEWS: Today we received Orphan Drug Designation from the U.S. FDA for our investigational, targeted therapy for neuroendocrine carcinomas, aggressive malignancies with limited treatment options. Learn more: bit.ly/4hLXpIo

The EMA granted Orphan Drug Designation to our potential first-in-class targeted antibody-drug conjugate for pulmonary neuroendocrine carcinomas (pNECs). Learn how we’re advancing much-needed treatment options for pNECs such as small cell lung cancer: tinyurl.com/4hcywupf

#Breaking: China's NMPA approved our BLA for a new treatment for adults with recurrent or metastatic cervical cancer. We will leverage our experienced oncology team in China to bring this therapy to patients in need. Learn more: tinyurl.com/459b4h6y

This weekend, we're at #ASCO26, highlighting the ongoing trial evaluating our investigational treatment for small-cell lung cancer. Read more here: tinyurl.com/nt4nybuf

#Breaking: The U.S. FDA granted Fast Track designation to our experimental targeted antibody-drug conjugate for extrapulmonary neuroendocrine carcinomas. Learn more about this milestone: tinyurl.com/385hujju

Today, we shared Q1 earnings results and notable commercial updates. Read our full earnings announcement: tinyurl.com/32e9wj7p

#NEWS: Dr. Thummalapalli speaks to @ecancer about early-phase results evaluating zoci, a novel DLL3-targeting antibody-drug conjugate, in patients with advanced neuroendocrine carcinomas who have progressed after platinum-based chemotherapy. @rohit_thum bit.ly/49qWXKF

#Breaking at #AAI2026: We're sharing positive preclinical study results from our investigational bispecific antibody in atopic dermatitis and other disease models. Learn more: tinyurl.com/4wbxvmr2

At #AACR26, we will present data demonstrating the progress of our #oncology pipeline, including important new data for our investigational treatment for people with small-cell lung cancer. Learn more: tinyurl.com/4cn6zmes

#NEWS: We announced a clinical collaboration with @Boehringer to pioneer a potential dual DLL3-targeting investigational combination for small-cell lung cancer and other neuroendocrine carcinomas. Learn more: tinyurl.com/2vyyhy5r #SLC #Innovation #Oncology

#NEWS: Zai Lab announces global clinical trial collaboration and supply agreement with @Amgen Learn more: lnkd.in/gBVS8nJC

#NEWS: Zai Lab will present new data on three internally developed oncology candidates at #AACR26, including zoci (DLL3 ADC), ZL‑6201 (LRRC15 ADC), and ZL‑1222 (PD‑1/IL‑12). Learn more: tinyurl.com/398k89ek #ADC #Oncology #Immunotherapy

#NEWS: Zai Lab announces fourth quarter and full-year 2025 financial results along with recent product highlights and corporate updates. Learn more about our pipeline progress and healthcare innovation: tinyurl.com/5753jbdd #earnings #financialresults #oncology #ADC

Celebrating five years of partnership with @argenxglobal. Together, we’ve accelerated development, expanded patient access, and supported thousands across China—including those living with gMG and CIDP. Grateful for our teams driving impact and innovation forward. #LifeSciences

#NEWS: Zai Lab will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco today @ 3PM PT / 6PM ET. Learn more about our 2026 strategic priorities and global pipeline progress: bit.ly/3NgL81C #JPM26 #Innovation #ADC #oncology

#NEWS: Zai Lab dosed the first participant in our Global Phase 1/1b study of ZL-1503, a potential first-in-class IL-13/IL-31R bispecific antibody for the treatment of atopic dermatitis. Discover the potential of ZL-1503: bit.ly/4rFqqs5